Actively Recruiting
Study of GCAR1 CAR T-Cell Therapy for Adults with Relapsed or Refractory GPNMB-Expressing Solid Tumors Including ASPS, TNBC, and RCC
Led by Canadian Cancer Trials Group · Updated on 2026-10-16
30
Participants Needed
4
Research Sites
247 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating GCAR1, a chimeric antigen receptor CAR T-cell therapy, for patients with certain relapsed or refractory solid tumors that express a protein called GPNMB. The study aims to identify the highest dose of GCAR1 that can be tolerated without causing very severe side effects and to observe its effects on alveolar soft part sarcoma ASPS, triple negative breast cancer TNBC, and renal cell carcinoma RCC. This phase I trial focuses on establishing recommended doses for further testing. Participants will receive GCAR1 through a dose escalation process to find the best tolerated dose. Before receiving GCAR1, participants will be treated with the drugs fludarabine and cyclophosphamide. The study involves testing increasing doses of GCAR1 in participants with confirmed high levels of GPNMB in their tumors. Prior systemic therapies must have been completed or progressed as specified for each cancer type. The trial is designed as a single-group study where all participants receive the investigational treatment. During the study, participants will be closely monitored for side effects and treatment responses. Evaluations include measuring tumor response using RECIST 1.1 criteria, tracking adverse events, and assessing the duration of response over three years. Participants must be accessible for treatment and follow-up at the study center for at least 12 months. Safety and treatment effects will be carefully assessed to determine the recommended phase II dose of GCAR1.
CONDITIONS
Brief Title
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Research Team
L
Laura Pearce
M
Mariam Jafri
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here